Chronic wounds, or wounds that fail to proceed through an orderly and timely repair process, affect some 6.5 million patients in the United States with an associated cost of care over $50 billion annually. These ailments can require lengthy treatments at significant costs to the healthcare system. Major disability, poor quality of life, and reduced productivity contribute to the growing financial burden. The number of people affected by a chronic wound is expected to increase as the population ages and the incidence of diabetes and obesity continues to rise worldwide. Wound duration is an independent risk factor for infection, hospitalization, and amputation, and contributes to patient morbidity, mortality, and cost of care.
Osiris Therapeutics, Inc. is committed to developing regenerative medicine products that provide better solutions to address the unmet needs of hard-to-treat wounds, including diabetic foot ulcers and venous leg ulcers. Osiris's proprietary manufacturing process retains the native characteristics and inherent functionality of placental tissue, a tissue that has been used in the wound care space for over 100 years. The results are safe, easy-to-use products that have been shown to be beneficial in supporting natural wound repair and decreasing the time it takes to close chronic wounds.
- Describe the science of placental membranes and their relevance in chronic and complex wounds
- Review published clinical study results on the use of placental membranes in complex wounds with exposed bone and tendons
- Explore clinical case studies on the use of placental membranes in a variety of chronic and complex wounds